G1 Therapeutics Inc logo

G1 Therapeutics Inc Share Price (NASDAQ: GTHX)

Live

Last updated on

Bell Icon

This instrument is not available for trading on the INDmoney app on 17 Sep 2024

Check the interactive G1 Therapeutics Inc Stock chart to analyse performance

G1 Therapeutics Inc Key Stats

Check G1 Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.0
Open
$7.15
Market Capitalization
$377.2M
Today's Volume
$1.3M
Revenue TTM
$58.2M
EBITDA
$-37.4M
Earnings Per Share (EPS)
$-0.86
Profit Margin
-76.93%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-109.01%

Global Institutional Holdings in G1 Therapeutics Inc

  • Name

    Holdings %

  • BlackRock Inc

    5.84%

  • Vanguard Group Inc

    4.72%

  • Woodline Partners LP

    2.58%

  • Renaissance Technologies Corp

    2.36%

  • Geode Capital Management, LLC

    2.05%

  • State Street Corp

    1.57%

Analyst Recommendation on G1 Therapeutics Inc Stock

Rating
Trend

Buy

    83%Buy

    8%Hold

    8%Sell

Based on 12 Wall street analysts offering stock ratings for G1 Therapeutics Inc(by analysts ranked 0 to 5 stars)

About G1 Therapeutics Inc

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Organization
G1 Therapeutics Inc
Employees
100
CEO
Mr. John E. Bailey Jr.
Industry
Health Technology

Important FAQs about investing in GTHX Stock from India :

What is G1 Therapeutics Inc share price today?

G1 Therapeutics Inc share price today is as on . G1 Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for G1 Therapeutics Inc share?

G1 Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. G1 Therapeutics Inc stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in G1 Therapeutics Inc Stock (GTHX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for G1 Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in G1 Therapeutics Inc Shares .

What is the minimum amount required to buy G1 Therapeutics Inc Stock (GTHX) from India?

Indian investors can start investing in G1 Therapeutics Inc (GTHX) shares with as little as ₹93.46 or $1 (as of March 21, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹934.60 in G1 Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on March 21, 2026). Learn more about fractional shares .

What are the returns that G1 Therapeutics Inc has given to Indian investors in the last 5 years?

G1 Therapeutics Inc stock has given 0.0% share price returns and 29.12% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?